DeepCyte Launches Single-Cell Metabolomic Reference Atlas of Drug Toxicity Mechanisms
DeepCyte launched the DeeTox Atlas™, a single-cell metabolomic reference atlas of drug toxicity mechanisms. Enterprise pilot programs with global pharmaceutical companies are expected to begin in the coming months.
DeeTox Atlas is described as a foundation dataset built from two independent single-cell metabolomics perturbation studies, spanning approximately 100 toxicant compounds, 300,000 cells, and ~500 metabolites per cell—over 3,000 single-cell measurementsper compound across six biological replicates. Each compound is mapped to a curated four-level hierarchy of toxicity mechanisms anchored to established Adverse Outcome Pathways (AOPs), according to the company.
Rather than generating new wet-lab data for every compound, DeepCyte trains a foundation model capable of predicting toxicity mechanisms for compounds it has never measured, said Theodore Alexandrov, co-founder and CEO of DeepCyte, adding that as the atlas expands, the platform becomes increasingly scalable, reducing laboratory dependence while improving predictive performance.
“AI in toxicology is only as good as the biological data it learns from. DeeTox Atlas lets us find subtle molecular patterns tied to key toxicity mechanisms—patterns our validation studies show are expressed in small subpopulations of cells and are effectively invisible to methods lacking single-cell resolution—and turn them into predictive models,” explained Alexandrov. “Our vision is to move toxicology from reactive laboratory testing toward predictive, mechanism-based AI that surfaces and explains safety liabilities earlier in drug discovery.”
The Atlas will expand with more compounds, mechanisms, and biochemical and clinical data, making predictions more actionable for toxicologists, medicinal chemists, and safety scientists, noted Alexandrov.
Industry NewsArtificial intelligenceDrug discoveryMetabolomics analysisRisk assessmentToxicityToxicologyDeepCyteDeeTox Atlas™Previous article
AI Identifies Pre-existing Antimicrobial Antibody Profile That May Predict Immune Response to VaccinationNext article
From Models to Agents: The Next Phase of AI Adoption in Molecular DiscoveryAlso of Interest
CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving MiceSmarter Cell Culture Starts with Better MediaRevvity Signs Agreement to Acquire Human Cell DesignTop 10 Contract Development and Manufacturing Organizations 202610 CDMO Up & Comers 2026Harnessing Real-Time DataRelated Media
Data Integrity as the Foundation for AISmall Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale-Up, and SustainabilityBeyond the Technology: AI Readiness in Regulated LaboratoriesAACR 2026 Video Update: Cancer Research Edges Toward an AI-Driven EraReporting Live from JPM 2026: Alex Philippidis and Jonathan Grinstein, PhDAI in Protein Design: Hype vs. Reality Explained by David BakerTop 5ResourcesRecommended For YouPodcast
Touching Base
Touching Base is the dynamic podcast series from the editors ofGEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.Start listening today!
Stay up to date with the lasted episodes of Touching Base bysubscribing to theGENPodcast Newsletter
